Emcure Pharmaceuticals partners with Roche to distribute transplant and CKD therapies in India 

• Key Highlights: 
  Emcure Pharmaceuticals has signed a distribution agreement with Roche to commercialize select products from Roche’s nephrology and transplant medicine portfolio in India, aiming to expand patient access to therapies for chronic kidney disease (CKD), anemia management, and transplant care. 
• Under the agreement, Emcure will distribute key Roche brands including CellCept, an immunosuppressant widely used in organ transplantation, along with Mircera and Neorecormon, established therapies used to manage anemia in patients with CKD. 
• The partnership combines Roche’s transplant and nephrology innovations with Emcure’s strong presence in anemia management and renal care, with both companies aiming to broaden access to these treatments and support improved outcomes for patients with kidney disease and transplant needs across India. 

Implications: 

Emcure grabs massive share in India’s exploding CKD/anemia market, challenging Sun Pharma/Jubilant while locking in transplant dominance through Roche’s gold-standard brands. 
Tier-2/3 penetration skyrockets as Emcure’s ground game outflanks smaller players, fueling PE frenzy around nephrology platforms amid dialysis boom. 
Deal cements India as kidney care export hub. 

Source: Expresspharma